Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

NCT04880434 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Mantle Cell Lymphoma

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: Brexucabtagene autoleucel

Sponsor

Kite, A Gilead Company